MASHINIi

10X Capital Venture Acquisition Corp. III.

VCXB.US | Activities of holding companies

10X Capital Venture Acquisition Corp. III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. These companies, also known as SPACs (Special Purpose Acquis...Show More

Ethical Profile

Mixed.

10X Capital Venture Acquisition Corp. III (VCXB.US) is a Special Purpose Acquisition Company (SPAC), with its ethical profile largely determined by its future acquisitions. The company is currently combining with Addimmune, which focuses on AGT103-T, an investigational cell therapy for potentially curing HIV. Phase 1 trials for AGT103-T reportedly showed positive safety results in seven patients, indicating a potential positive impact on "Better Health for All." As a blank check company, VCXB.US has no direct operations, employees, or supply chain, making assessments for areas like "Fair Pay & Worker Respect" or "Planet-Friendly Business" contingent on its acquired entity. VCXB.US also received a NYSE Regulation notice regarding non-compliance with minimum public shareholder requirements. Its ethical standing remains primarily prospective.

Value Scores

Better Health for All30
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

30

Addimmune, the company VCXB.US is merging with, is a clinical-stage cell and gene therapy company entirely devoted to developing AGT103-T, a potential functional cure for HIV.

1
This focus on a revolutionary health benefit means 100% of its business is aimed at health improvement, and most of its $75 million capital raised to date has been spent on this innovation.
2
The company has no revenue from products with negative health outcomes. Clinical trials for AGT103-T have received IRB approval and participant informed consent, with detailed protocols for patient safety during treatment interruptions.
3
The company publishes clinical trial data and safety results, and discloses various business and operational risks.
4

Fair Money & Economic Opportunity

0

VCXB.US is a Special Purpose Acquisition Company (SPAC) formed for the purpose of effecting a merger, as explicitly stated in the provided articles.

1
Its business model does not involve providing consumer financial services such as lending, deposit services, or offering financial products. Therefore, all KPIs related to fair money and economic opportunity, which assess direct engagement in consumer finance, are not applicable to VCXB.US's operations.

Fair Pay & Worker Respect

0

No evidence available to assess 10X Capital Venture Acquisition Corp. III on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

The provided article discusses general supply chain risk but contains no specific data relevant to VCXB.US or its fair trade and ethical sourcing practices.

1
Therefore, no KPIs can be scored based on the available evidence.

Honest & Fair Business

0

The company received a notice from NYSE Regulation on January 29, 2024, for non-compliance with Section 1003(b)(i) of the NYSE American LLC Company Guide, specifically for having fewer than 300 public shareholders.

1
A compliance plan was due by February 28, 2024, with a target compliance date of January 14, 2025.
2
The article explicitly states this was a regulatory issue, not a violation or fine.
3

Kind to Animals

0

No specific, concrete evidence was found in the provided articles for VCXB.US (10X Capital Venture Acquisition Corp. III) regarding any of the 'Kind to Animals' KPIs. Information found in some articles pertains to a different entity, 10X Capital Venture Acquisition Corp. II (VCXA.US), and was therefore excluded.

1

No War, No Weapons

0

VCXB.US is a Special Purpose Acquisition Company (SPAC) that is merging with Addimmune, a clinical-stage gene and cell therapy company focused on developing a functional cure for HIV.

1
The provided articles describe the business combination and the nature of Addimmune's medical technology. The proposed transaction, expected to close in Q1 2024, values Addimmune at $500 million pre-money, with a potential earnout of up to $300 million tied to clinical and pricing milestones.
2
No information was found in the articles regarding VCXB.US's or Addimmune's involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding investments, or any other activities related to the "No War, No Weapons" ethical value.

Planet-Friendly Business

0

PrimeBlock, the operating company VCXB.US plans to merge with, sources approximately 60% of its power from non-carbon emitting sources.

1
The company aims to minimize its environmental impact and has a strategic commitment to contract with energy providers focused on carbon-neutral operations.
2
It also plans to offset the remainder of its power usage not from non-carbon emitting sources.
3
A key partner, the Tennessee Valley Authority, has committed to net-zero carbon emissions by 2050.
4

Respect for Cultures & Communities

0

VCXB.US is a blank check company (SPAC) currently involved in a merger to form Addimmune.

1
The provided articles focus on its financial and regulatory compliance, including a transfer of listing from NYSE to NYSE American
2
and challenges with shareholder requirements
3
. As a blank check company, its current operations do not directly involve community engagement or cultural impact. Consequently, the articles do not contain any specific data points or metrics relevant to the 'Respect for Cultures & Communities' KPIs, leading to the omission of all KPIs.

Safe & Smart Tech

0

No specific evidence was found regarding VCXB.US's performance across any of the 'Safe & Smart Tech' KPIs. The provided articles discuss general industry trends in venture capital, AI, and cybersecurity, or detail the delisting of VCXB.US warrants

1
. There is no information on the company's data protection, cybersecurity investments, AI ethics governance, or any other relevant practices for VCXB.US specifically.

Zero Waste & Sustainable Products

0

No specific, concrete data points or initiatives related to zero waste and sustainable products for VCXB.US or the merged entity REE Automotive Ltd. were found in the provided articles. The articles consistently state a lack of specific data or mention of VCXB.US regarding these metrics, and for REE Automotive, they explicitly note the absence of publicly available data for zero waste or sustainable product metrics.

1

Own 10X Capital Venture Acquisition Corp. III?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.